Onychomycosis is also known as fungal nail infections, caused by yeasts, particularly Trichophyton rubrum and Trichophyton mentagrophytes. Peoples having weak immune system are more susceptible to the disease. Onychomycosis is classified into four types, distal subungual onychomycosis, proximal subungual onychomycosis, white superficial onychomycosis and candida infections of the nail. There are some risk factors associated with onychomycosis such as diabetes and peripheral artery disease, psoriasis, wearing tight shoes, weakened the immune system, damaged nails, athlete’s foot and frequent contact with fungi. Diabetic foot syndrome or diabetic foot ulcer is the severe complications of onychomycosis in diabetic patients. Moberg Pharma AB is in the process of developing MOB-015 as a squalene monooxygenase inhibitor for the treatment of onychomycosis. Hallux, Inc. is in the process of developing HTS-519 as a squalene monooxygenase inhibitor for the treatment of onychomycosis. Some of the companies/universities having the pipeline of onychomycosis include Moberg Pharma AB, Hallux, Inc., Western University of Health Sciences, and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.